Mastodon

Sodium nucleinate (Tablets, Powder) Instructions for Use

ATC Code

L03AX (Other immunostimulants)

Clinical-Pharmacological Group

Immunomodulator

Pharmacotherapeutic Group

Leukopoiesis stimulator

Pharmacological Action

Sodium nucleinate is isolated from baker’s yeast.

Sodium nucleinate possesses the activity of a polyclonal immunostimulant, regulating the migration of T-lymphocytes and the processes of cooperation between T- and B-lymphocytes, enhances the phagocytic activity of macrophages and the production of factors of nonspecific protection.

It has a wide spectrum of biological activity.

It accelerates tissue regeneration processes, stimulates bone marrow activity and leukopoiesis.

Indications

As part of complex therapy for infectious diseases occurring against the background of secondary immunodeficiency states:

  • Chronic nonspecific lung diseases;
  • Chronic recurrent viral and bacterial infections;
  • Secondary immunodeficiency states associated with aging;
  • Correction of leukopenia and agranulocytosis.

ICD codes

ICD-10 code Indication
A49.9 Unspecified bacterial infection
A60 Anogenital herpesviral infection [herpes simplex]
B00 Herpesviral [herpes simplex] infections
B02 Zoster [herpes zoster]
B19 Unspecified viral hepatitis
B25 Cytomegaloviral disease
D70 Agranulocytosis
D84.9 Immunodeficiency, unspecified
D89 Other disorders involving the immune mechanism, not elsewhere classified
J18.9 Pneumonia, unspecified
J42 Unspecified chronic bronchitis
J44 Other chronic obstructive pulmonary disease
ICD-11 code Indication
1A94.Z Anogenital herpes simplex virus infection without further specification
1C41 Bacterial infection of unspecified site
1D82.Z Cytomegaloviral disease, unspecified
1E5Z Unspecified viral hepatitis
1E91.Z Herpes zoster, unspecified
1F00.Z Infections due to herpes simplex virus, unspecified
4A0Z Unspecified primary immunodeficiencies
4B00 Quantitative defects of neutrophils
4B00.00 Constitutional neutropenia
4B00.01 Acquired neutropenia
4B4Z Diseases of the immune system, unspecified
CA20.1Z Chronic bronchitis, unspecified
CA22.Z Chronic obstructive pulmonary disease, unspecified
CA40.Y Other specified pneumonia
CA40.Z Pneumonia, microorganism not specified
MA15.0 Bacteremia

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Powder

Orally, after meals.

For adults, the daily dose is 1-2 g in 3-4 divided doses.

The course of treatment is 10 days (depending on the severity of the disease – up to 6 weeks).

A course of therapy with the drug (including for the treatment of chronic diseases) can be conducted 2-3 times during the year.

Tablets

Orally, after meals. The daily dose is 1-2 g in 3-4 divided doses. The course of treatment is 10 days (depending on the severity of the disease – up to 6 weeks).

For elderly and senile patients with reduced immune status – 1-1.5 g/day for 2-3 weeks, 2 times a year (in spring and autumn).

For leukopenia in adults – 1 tablet 2-3 times a day, the course of treatment is determined individually, averaging 10 days.

A course of therapy with the drug (including for the treatment of chronic diseases) can be conducted 2-3 times during the year.

Adverse Reactions

Allergic reactions are possible.

Contraindications

  • Hypersensitivity to the drug components;
  • Pregnancy, lactation period.

Use in Pregnancy and Lactation

Contraindicated during pregnancy and lactation.

Pediatric Use

Not used in children.

Drug Interactions

None identified.

Storage Conditions

In a dry, light-protected place, out of reach of children, at a temperature not exceeding 25°C (77°F).

Shelf Life

Shelf life – 2 years.

Dispensing Status

By prescription.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Biosintez, PJSC (Russia)

Dosage Form

Bottle Rx Icon Sodium nucleinate Powder for oral administration 0.5 g: bottle 1 pc.

Dosage Form, Packaging, and Composition

Powder for the preparation of oral suspension 1 bottle
Sodium nucleinate 500 mg

500 mg – Bottles with a volume of 10 ml (50) – cardboard boxes.

Marketing Authorization Holder

Biosintez, PJSC (Russia)

Dosage Form

Bottle Rx Icon Sodium nucleinate Film-coated tablets, 250 mg: 10, 20, or 50 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets 1 tab.
Sodium nucleinate 250 mg

Excipients: calcium stearate, potato starch, low molecular weight polyvinylpyrrolidone, refined sugar, aerosil, beeswax, titanium dioxide, food gelatin, basic magnesium carbonate, sunflower oil, paraffin, talc.
50 pcs. – polymer jars (1) – cardboard packs.

TABLE OF CONTENTS